Article Text

Download PDFPDF

THU0608 Association between allopurinol dose-titration and serum uric acid levels in gout patients: us electronic health record data
  1. A-C Fu1,
  2. DC Taylor2,
  3. DS Reasner2
  1. 1Ironwood Pharmaceuticals, Inc., Cambridge, Ashmore and Cartier Islands
  2. 2Ironwood Pharmaceuticals, Inc., Cambridge, United States


Background Allopurinol is a first-line urate lowering therapy for patients with gout. The American College of Rheumatology guidelines recommend allopurinol dose-titration to maintain serum uric acid (sUA) levels <6 mg/dl.

Objectives To understand allopurinol dose-titration relative to sUA levels.

Methods This retrospective study used the de-identified Humedica electronic medical record database. The study included all sUA and allopurinol records among gout patients (ICD-9-CM: 274.xx) ≥18 years old with first gout diagnosis in 2007 – 2015. An episode was defined as an allopurinol initial dose (ID) prior to (closest) and titrated dose (TD) after (within 30 days) an sUA test. Dose-titration was categorized as an episode with a dose-change (up-titration: ID < TD; down-titration: ID > TD), or no-dose-change (ID = TD). For multiple different doses recorded on the same prescription date, the sum of doses was taken as daily dosage. Episodes were considered uncontrolled when sUA ≥6 mg/dl. Descriptive episode-level analyses were performed.

Results Within 64,609 episodes, 57% of episodes were uncontrolled (sUA: 6 to <8 mg/dl: 38%; 8 to <10 mg/dl: 15%; ≥10mg/dl: 4%). Seventy-one percent of uncontrolled episodes were no-dose-change, 21% were up-titrated, and 7% were down-titrated. Within no-dose-change episodes, 51% were uncontrolled and lower doses corresponded to higher percentages of uncontrolled episodes (<100mg/day: 88%; 100mg/day: 70%; >100, <300 mg/day: 49%; 300mg/day: 38%; >300mg/day: 36%). Seventy-eight percent of dose-change episodes were uncontrolled, of which 100 to 300 mg/day (39%) was the most frequent dose titration. Overall, the most frequent TD was 300 mg/day (52%) followed by 100mg/day (36%), >100 – <300mg/day (8%), >300mg/day (3%), and <100mg/day (<1%).

Conclusions Allopurinol dose is not generally titrated regardless of sUA control. This pattern suggests a need for active management of patients with gout with uncontrolled sUA including consideration of new treatment options in addition to allopurinol.


  1. Juraschek SP et al. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015 Apr;67(4):588–92.

  2. Khanna D et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431–46.


Acknowledgements This study was funded by Ironwood Pharmaceuticals.

Disclosure of Interest A.-C. Fu Employee of: Employee of Ironwood Pharmaceuticals, D. Taylor Employee of: Employee of Ironwood Pharmaceuticals, D. Reasner Employee of: Employee of Ironwood Pharmaceuticals

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.